Esophageal cancer
Conditions
Interventions
Case series:Nil
Sponsors
Yijishan Hospital, Wannan Medical College
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Age >=18 years old, no gender limit; 2. Patients with esophageal squamous cell carcinoma confirmed by histopathological and/or immunohistochemical examination; 3. Patients with first-line esophageal squamous cell carcinoma have at least one measurable lesion (the CT scan length of the tumor lesion is >= 10 mm, the CT scan length of the lymph node lesion is >=15 mm, and the scan thickness is not greater than 6 mm); 4. ECOG score: 0-2 points; 5. The expected survival period is >= 3 months; 6. The damage caused by the subject receiving other treatments has recovered, among which the interval between receiving nitroso or mitomycin is = 4 weeks, and the wound has healed completely; main organ function normal; 7. The main organs are functioning normally, that is, they meet the following standards: (1) Routine blood examination standards must meet (no blood transfusion and blood products within 14 days): 1) HB >= 80 g/L; 2) ANC >= 1.5 x 10^9/L; 3) PLT >= 80 x 10^9/L; (2) The biochemical inspection shall meet the fol lowing standards: 1) TBIL 45 ml/min (Cockcroft-Gault formula); 8. Women of childbearing age must have taken reliable contraceptive measures or undergo a pregnancy test (serum or urine) within 7 days before enrollment, and the result is negative, and are willing to adopt appropriate methods during the trial and 8 weeks after the last trial drug administration contraception. For men, they must agree to use appropriate methods of contraception or have been surgically sterilized during the trial period and 8 weeks after the last trial drug administration; 9. The subject voluntarily joins the study and signs an informed consent form, with good compliance and cooperation with follow-up; 10. The researcher believes that it can benefit.
Exclusion criteria
Exclusion criteria: 1. Pregnant or breastfeeding women; suffering from high blood pressure and cannot be reduced to normal after treatment with antihypertensive drugs; Those within the range (systolic blood pressure > 140 mmHg, diastolic blood pressure > 90 mmHg) suffer from grade I or higher; Upper myocardial ischemia or myocardial infarction, arrhythmia and grade II cardiac insufficiency; 2. There are factors that significantly affect the absorption of oral drugs, such as inability to swallow, chronic diarrhea and intestines Obstruction etc.; 3. Have a bleeding tendency or are receiving thrombolysis or anticoagulation therapy; 4. With clear gastrointestinal bleeding concerns (such as local active ulcer lesions, fecal occult blood++ above), a history of gastrointestinal bleeding within 6 months; 5. Symptomatic central nervous system metastasis; 6. The investigator judges other conditions that may affect the conduct of clinical research and the determination of research results.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Progression-free survival; | — |
Countries
China
Contacts
Public ContactChen Yihong
Yijishan Hospital, Wannan Medical College
Outcome results
None listed